Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | 8,990.91% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | 8,990.91% | -- |
| Cost of Revenue | -32.21% | -38.35% | -19.73% | -3.29% | 18.29% |
| Gross Profit | 32.21% | 35.39% | 16.25% | 469.73% | -20.42% |
| SG&A Expenses | -30.43% | -21.78% | -15.43% | -0.74% | -12.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.61% | -32.69% | -18.21% | -2.36% | 5.66% |
| Operating Income | 31.61% | 30.59% | 15.95% | 292.33% | -6.78% |
| Income Before Tax | 34.29% | 33.07% | 9.66% | 332.98% | -8.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.29% | 33.07% | 9.66% | 332.98% | -8.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.29% | 33.07% | 9.66% | 332.98% | -8.44% |
| EBIT | 31.61% | 30.59% | 15.95% | 292.33% | -6.78% |
| EBITDA | 31.70% | 30.65% | 15.66% | 297.82% | -7.24% |
| EPS Basic | 34.81% | 23.24% | 10.53% | 331.41% | -4.48% |
| Normalized Basic EPS | 34.81% | 23.27% | 19.03% | 331.48% | -4.47% |
| EPS Diluted | 34.81% | 22.49% | 10.26% | 326.03% | -4.48% |
| Normalized Diluted EPS | 34.81% | 23.27% | 19.03% | 326.44% | -4.47% |
| Average Basic Shares Outstanding | 0.80% | -12.80% | 0.95% | 0.67% | 3.79% |
| Average Diluted Shares Outstanding | 0.80% | -12.80% | 0.95% | 2.90% | 3.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |